MSF Warns Global Shortage Of Drug-Resistant TB Treatment Likely

As countries increase the use of the GeneXpert test, a two-hour molecular TB test released in 2010, “enabl[ing] them to diagnose more patients with drug-resistant tuberculosis (DR-TB), a worldwide shortage of the drugs to treat these patients is likely, Medecins Sans Frontieres (MSF) warns,” according to PlusNews.

“South Africa, which has the world’s fifth-largest burden of multi-drug resistant (MDR) TB cases, will replace all microscope-based TB diagnoses with faster, more sensitive GeneXpert testing within two years,” which “could double the number of MDR-TB cases diagnosed … according to Norbert Ndjeka, director of DR-TB, TB and HIV at the South African National Department of Health,” the news agency reports. “Treating MDR-TB patients takes up about half South Africa’s TB budget” already, and “MSF has estimated that without lower DR-TB costs, South Africa will be spending as much as $630 million on treatment by 2015,” PlusNews writes (8/16).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.